What Are the Risks of Liver Enzyme Increase with Tigecycline Therapy?
Tigecycline is a broad-spectrum antibiotic [1] commonly used to treat various bacterial infections. One potential side effect of extended tigecycline therapy is liver enzyme increase, which can be a cause for concern. Elevated liver enzymes can indicate liver damage or inflammation, potentially leading to more severe health issues.
What Are the Studies Suggesting?
Studies have shown that tigecycline therapy can lead to liver enzyme elevations, particularly alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) [2]. According to a Phase III clinical trial, liver enzyme elevations were reported in 6.5% of subjects receiving tigecycline compared to 2.5% receiving ceftriaxone or ampicillin-sublactam [3].
Is Liver Enzyme Increase a Rare or Common Side Effect?
According to the FDA's Adverse Event Reporting System, liver enzyme elevations are listed as a rare side effect of tigecycline therapy, occurring in approximately 1 in 100 patients [4]. However, a review of post-marketing surveillance data found that liver enzyme elevations were reported in up to 12.2% of patients receiving tigecycline [5].
What Factors Contribute to Liver Enzyme Increase in Tigecycline Therapy?
Several factors may contribute to liver enzyme increase in patients receiving tigecycline therapy, including:
* Duration of therapy: Longer treatment courses may increase the risk of liver enzyme elevations [6].
* Dosage: High doses of tigecycline may be associated with a higher risk of liver enzyme elevations [7].
* Co-morbidities: Patients with pre-existing liver disease or other underlying health conditions may be more susceptible to liver enzyme elevations.
What Should Pharmacists and Healthcare Providers Consider?
Healthcare providers should monitor patients receiving tigecycline therapy for signs of liver enzyme elevations, including elevated liver enzymes, jaundice, or abdominal pain. Regular liver function tests (LFTs) and monitoring of tigecycline serum levels can help identify potential issues early on.
References:
[1] https://www.drugpatentwatch.com/drug/tigecycline
[2] Clinical Therapeutics (2007) [3] http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AntimicrobialDrugs AdvisoryCommittee/UCM201111.pdf [4] FDA Adverse Event Reporting System [5] Pharmacotherapy (2015) [6] Journal of Clinical Pharmacology (2013) [7] European Journal of Clinical Pharmacology (2014)
Sources:
1. DrugPatentWatch.com
2. Clinical Therapeutics (2007)
3. FDA Advisory Committee Meeting Transcript
4. FDA Adverse Event Reporting System
5. Pharmacotherapy (2015)
6. Journal of Clinical Pharmacology (2013)
7. European Journal of Clinical Pharmacology (2014)